Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by novel approvals for neuromuscular disease therapeutics, growing newborn screening tests, and huge unmet need for neuromuscular disease therapeutics.
The neuromuscular disease therapeutics market is segmented as below:
By Type
- Biologics
- Small molecules
By End-user
- Hospitals
- Clinics
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the neuromuscular disease therapeutics market covers the following areas:
- Neuromuscular disease therapeutics market sizing
- Neuromuscular disease therapeutics market forecast
- Neuromuscular disease therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary
The publisher recognizes the following companies as the key players in the global neuromuscular disease therapeutics market: Aquestive Therapeutics Inc., Bausch Health Companies Inc., Biogen Inc., Brainstorm Cell Therapeutics Inc., Cytokinetics Inc., F. Hoffmann La Roche Ltd., Ionis Pharmaceuticals Inc., Mitsubishi Chemical Corp., Mylan NV, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., PTC Therapeutics Inc., Sanofi, Sarepta Therapeutics Inc, SGPharma Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Troikaa Pharmaceuticals Ltd., Viatris Inc., and AFM-Telethon.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is technological advances in neuromuscular disease therapy.'
According to the report, one of the major drivers for this market is the novel approvals for neuromuscular disease therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aquestive Therapeutics Inc.
- Bausch Health Companies Inc.
- Biogen Inc.
- Brainstorm Cell Therapeutics Inc.
- Cytokinetics Inc.
- F. Hoffmann La Roche Ltd.
- Ionis Pharmaceuticals Inc.
- Mitsubishi Chemical Corp.
- Mylan NV
- Nippon Shinyaku Co. Ltd.
- Novartis AG
- Pfizer Inc.
- PTC Therapeutics Inc.
- Sanofi
- Sarepta Therapeutics Inc
- SGPharma Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Troikaa Pharmaceuticals Ltd.
- Viatris Inc.
- AFM-Telethon